| P50 | author | Alexander Shimabukuro-Vornhagen | Q42430338 |
| | Michael von Bergwelt-Baildon | Q47158294 |
| | Sebastian Theurich | Q47158304 |
| | Kerstin Wennhold | Q56943357 |
| P2860 | cites work | Dendritic cells and the control of immunity | Q27860918 |
| | Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species | Q28274570 |
| | Altered antigen presentation in mice lacking H2-O | Q28504672 |
| | The dendritic cell system and its role in immunogenicity | Q29619870 |
| | Conditional immortalization of human B cells by CD40 ligation | Q33316020 |
| | Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis | Q33886261 |
| | Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity | Q33956237 |
| | CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma | Q34014497 |
| | Biology of interleukin-10. | Q34152272 |
| | Homing and cellular traffic in lymph nodes | Q34282818 |
| | Designer dendritic cells for tolerance induction: guided not misguided missiles | Q34319943 |
| | Pneumococcal disease: prospects for a new generation of vaccines | Q34332913 |
| | Haemophilus influenzae type b conjugate vaccines | Q34349892 |
| | Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy | Q34478042 |
| | Mouse and human dendritic cell subtypes | Q34576401 |
| | Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression | Q35146131 |
| | Mechanisms and functional significance of tumour-induced dendritic-cell defects | Q35968465 |
| | Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal | Q36361532 |
| | Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming | Q36371607 |
| | CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells | Q36601966 |
| | In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins | Q36628925 |
| | Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. | Q36764907 |
| | Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells | Q36868786 |
| | Twelve immunotherapy drugs that could cure cancers | Q37118201 |
| | CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy | Q37375643 |
| | Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. | Q37440696 |
| | TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy | Q37747519 |
| | Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation | Q37828473 |
| | Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon | Q40314779 |
| | Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro | Q40334381 |
| | C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. | Q40337403 |
| | B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. | Q40483578 |
| | Growing human B lymphocytes in the CD40 system | Q41660692 |
| | Long-Term Human B Cell Lines Dependent on Interleukin-4 and antibody to CD40 | Q41700086 |
| | The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells | Q41761209 |
| | CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants | Q42742311 |
| | RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy | Q42833829 |
| | Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application | Q43966225 |
| | Induction of CD4+ T-cell anergy and apoptosis by activated human B cells | Q44445127 |
| | Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. | Q45249223 |
| | CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. | Q48371221 |
| | Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. | Q51803494 |
| | Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. | Q51866457 |
| | CD40-CD40 ligand interactions stimulate B cell antigen processing. | Q52546961 |
| | Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. | Q53656344 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 631-637 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application | |
| P478 | volume | 12 | |